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Abstract
Background: Growth hormone (GH) mainly serves an endocrine function to regulate somatic growth, but also
serves an autocrine function in lung growth and pulmonary function. Several recent studies have demonstrated the
role of autocrine GH in tumor progression in some organs. However, it is not clear whether excessive secretion of
GH in the lungs is related to pulmonary nodule formation.
Methods: Firstly, the lung tissues dissected from mice were used for Western blotting and PCR measurement.
Secondly, the cultured cells were used for examining effects of GH on B16F10 murine melanoma cells. Thirdly, male
C57BL/6 mice were intravenously injected with B16F10 cells and then subcutaneously injected with recombinant
GH twice per week for three weeks. Finally, stably transfected pool of B16F10 cells with knockdown of growth
hormone receptor (GHR) was used to be injected into mice.
Results: We found that expression of GH was elevated in the lungs of DJ-1 knockout (KO) mice. We also examined
the effects of GH on the growth of cultured melanoma cells. The results showed that GH increased proliferation,
colony formation, and invasive capacity of B16F10 cells. In addition, GH also increased the expression of matrix
metalloproteinases (MMPs) in B16F10 cells. Administration of GH in vivo enhanced lung nodule formation in C57/B6
mice. Increased lung nodule formation in DJ-1 KO mice following intravenous injection of melanoma cells was
inhibited by GHR knockdown in B16F10 cells.
Conclusions: These results indicate that up-regulation of GH in the lungs of DJ-1 KO mice may enhance the
malignancy of B16F10 cells and nodule formation in pulmonary metastasis of melanoma.
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Background
DJ-1, a chaperon and anti-oxidative protein plays a crucial
role in oncogenesis [1, 2]. In addition, DJ-1 deficiency is
related to autosomal recessive Parkinson’s disease [3]. In
cancer cells, DJ-1 is known as an oncogene, which reacts
with activated Ras [4], a potential serum biomarker
secreted from breast cancer cells [1] and malignant mel-
anoma [5]. Overexpression of DJ-1 decreases the expres-
sion of Bax and suppresses caspase activation to promote
the growth of tumor cells [6]. Moreover, DJ-1 reportedly
mediates the phosphatidylinositol 3-kinase (PI3K) survival
pathway by negatively modulating the phosphatase and
tensin homolog (PTEN) tumor suppressor [7]. In our
previous studies, we found that DJ-1 deficiency upregu-
lates levels of IL-1β in the microenvironment of the lungs
and enhances metastasis of B16F10 cells in DJ-1 KO mice
[8]. Therefore, excess DJ-1 or DJ-1 deficiency in cancer
cells or their microenvironment, respectively, can both
lead to tumor progression. On the other hand, some stud-
ies have indicated that cytokines, such as IL-1β, can
promote growth hormone (GH) synthesis and secretion
in cultured cells [9, 10]. Thus, we will further examine
whether GH also plays a role in lung metastasis of
melanoma cells in DJ-1 KO mice.
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GH is reported to promote the development of certain
cancers. Epidemiological studies indicate that the risk of
colorectal cancer is increased in patients with acromegaly
and animal studies also demonstrate that up-regulated
levels of endogenous GH can cause mammary carcinoma
in transgenic mice [11, 12]. GH is mainly secreted from
the anterior pituitary and plays an important role in an
individual’s development [13]. It binds to the growth
hormone receptor (GHR) and exerts its effects through
insulin-like growth factor-I (IGF-I) signaling, which
controls cell proliferation, survival, and differentiation and
enhances cell cycle progression in many cell types [14].
Notably, GH can also be expressed locally in the lungs of
rats during fetal and neonatal development [15]. GHRs
are expressed in lung epithelia to enable GH effects [16]
and IGF-1 is widely expressed during rodent lung organo-
genesis [17]. These findings indicate that autocrine func-
tions of lung GH may enhance lung growth and survival
of surrounding cells. In addition, GH is expressed in
human mammary epithelial cells and autocrine GH can
promote survival, proliferation, and migration of the
human mammary carcinoma cell line MCF-7 and invasive
capacity of the human microvascular endothelial cell line
(HMEC-1) [18]. However, the autocrine effects of GH on
tumor cells in the lungs remain unclear.
GHR (but not GH) is reportedly expressed in melanoma
cells; therefore, melanoma cells can respond to GH stimu-
lation [19, 20]. GHR stimulation can promote cell invasion
and metastasis [21] and GHR deficiency down-regulates
the incidence of cancer [22]. We aimed to examine
whether there is a connection between lung GH expres-
sion and lung metastasis of GHR-expressing melanoma
cells. We found that GH expression was upregulated in
the lungs of DJ-1 KO mice, which increased the malignant
potential of melanoma cells.
Methods
Animals and cell culture
Male C57BL/6 mice as controls were supplied by the
Animal Center of Medical College, National Taiwan
University. Male DJ-1 KO mice donated by Dr. Tak W.
Mak (Toronto, ON, Canada) were on a C57BL/6 back-
ground. Mice at 5–6 weeks of age (20–25 g) were used,
given free access to food and water, and maintained at an
ambient temperature of 25 °C. All animal experiments were
reviewed and approved by the Institutional Animal Care
and Use Committee of the National Taiwan University.
B16F10 murine melanoma cells (from American Type
Culture Collection) were maintained in the cell culture in a
humidified incubator (5 % CO2, 37 °C) in Roswell Park
Memorial Institute (RPMI) medium supplemented with
10 % heat-inactivated fetal bovine serum (FBS) (Biological
Industries, Kibbutz Beit Haemek, Israel), 100 U/ml penicil-
lin, and 0.1 mg/ml streptomycin (Invitrogen, Carlsbad, CA).
RNA extraction, semi-quantitative RT-PCR, and real-time
quantitative PCR
RNA was extracted from tissues using TRIzol (MDBio
Inc., Taipei, Taiwan). Synthesis of cDNA was achieved
using MMLV RTase (Promega, Madison, Wisconsin,
USA). Synthesized cDNA was used as the template for
semi-quantitative RT-PCR and real-time quantitative
PCR. The primer sequences were as follows: mouse
growth hormone (GH): forward, 5′-CAGCCTGATGTT
CGGCACCTCGGA-3′ and reverse, 5′-GCGGCGACAC
TTCATGACCCGCA-3′; mouse IGF-1: forward, 5′-CT
GGACCAGAGACCCTTTGC-3′ and reverse, 5′-AG
AGCGGGCTGCTTTTGTAG-3′; mouse GAPDH: for-
ward, 5′-GCCATCAACGCCCCTTCATT-3′ and reverse,
5′-ACGGAAGGCCATGCCAGTGAGCTT-3′. Mouse
GH (Mm00433590_g1); IGF-1 (Mm00439560_m1); and
GAPDH (Mm99999915_g1) TaqMan probes were pur-
chased from Applied Biosystems (USA). The data
were analyzed by the StepOne Real-Time PCR system
(ABI, USA). The mRNA levels of GH and IGF-1 were
normalized to that of GAPDH and expressed relative
to the control using the formula 2-ΔΔCT.
Western blotting
Protein was extracted from tissues using radioimmu-
noprecipitation (RIPA) buffer containing 150 mM
NaCl; 50 mM Tris–HCl; 1 mM ethylene glycol tetraa-
cetic acid (EGTA); 1 % Nonidet P-40; 0.25 % deoxy-
cholate; 1 mM sodium fluoride; 50 mM sodium
orthovanadate; 5 mM phenylmethylsulfonyl fluoride
(PMSF); 10 μg/ml aprotinin; 10 μg/ml pH 7.5, leupep-
tin; and Halt protease inhibitor cocktail (Thermo, IL,
USA). Protein concentration was determined using
the bicinchoninic acid (BCA) protein assay kit (Pierce,
Rockford, IL). Bovine serum albumin was used as the
standard. Proteins were separated by SDS-PAGE and
transferred to polyvinylidene fluoride (PVDF) mem-
branes (Millipore, Billerica, MA). The membranes
were soaked in skim milk dissolved in phosphate-
buffered saline (PBS) for 1 h to block nonspecific
binding and the immune reaction was then allowed
to proceed overnight at 4 °C with the following pri-
mary antibodies: mouse anti-MMP-2; rabbit anti-
MMP-9; rabbit anti-MMP-13 (1:1000; Santa Cruz,
CA, USA); rabbit anti-DJ-1 (1:3000; Enzo Life Sci-
ences, UK); goat anti-growth hormone (1:1000; Santa
Cruz, CA, USA) goat anti-GHR (1:1000; R&D Sys-
tems, Minneapolis, MN, USA); and mouse anti-actin
(1:10,000; Chemicon, Temecula, CA). The blots were
then incubated with HRP-conjugated secondary anti-
body (1:10,000; GeneTex, CA, USA). Protein bands
were detected using an enhanced chemiluminescence
system (Thermo, IL, USA) and quantification was
determined by the ImageQuant 5.0 software.
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ELISA analysis of growth hormone
Sera prepared from wild type (WT) and DJ-1 knockout
mice were used for the quantitative measurement of
GH, using a mouse GH ELISA Kit (Millipore, Billerica,
MA, USA) according to the manufacturer’s instructions.
Samples were incubated with pre-coated primary GH
monoclonal antibody for 2 h. After washing away non-
specifically bound materials, an enzyme-linked poly-
clonal secondary antibody was added to the wells to
form a sandwich complex. A substrate solution was then
added to the wells for 30 min to yield color. Finally, a
stop solution was added, and the optical density (OD) of
each well was measured, using an ELISA reader set at
450 nm. GH concentrations in the samples were then
determined by comparing the OD of the samples with
the standard curve.
MTT reaction and BrdU ELISA analysis
B16F10 cells (5 × 103 cells) were seeded on 96-well
plates and incubated overnight in RPMI medium sup-
plemented with 10 % FBS. The medium was then re-
placed with serum-free medium containing GH (0.5, 5,
and 15 ng/ml; GenScript, Piscataway, USA). After 24 h
incubation, the supernatant was discarded and the
MTT solution (0.5 mg/ml, Sigma–Aldrich, St. Louis,
MO, USA) was added to each well for thiazolyl blue
tetrazolium bromide (MTT) analysis. After 30 min in-
cubation, the MTT solution was discarded and the for-
mazan crystal generated was completely dissolved in
dimethyl sulfoxide (DMSO). The absorbance was de-
tected with a spectrophotometer at 570 nm. Following
incubation of GH for 24 h, measurement procedures
for bromodeoxyuridine (BrdU) ELISA analysis were
followed according to manufacturer’s instructions
(Roche Applied Science, IN, USA). The incorporation
of BrdU was performed for 4 h and chemiluminescent
signals produced from the ELISA substrate were mea-
sured with a luminescent meter.
Colony formation
In a six-well culture plate, each well was divided into
three layers. The lower layer was 0.7 % solid agarose
(3 ml). The middle layer contained B16F10 cells (2 × 103
cells) incubated in 0.7 % solid agarose (1.5 ml); 10 %
FBS; RPMI (1.5 ml); and GH (1 and 10 ng/ml). The
upper layer was RPMI medium (3 ml) supplemented
with 10 % FBS and GH (1 and 10 ng/ml). Twelve days
later, the colonies were photographed and counted using
an inverted microscope.
Cell invasion
B16F10 cells (5 × 104 cells) suspended in 10 % FBS
RPMI medium were seeded to the cell culture inserts
with 8-μm pore polycarbonate filters (Coring, NY).
The filters were pre-coated with 25 μL Matrigel (BD
Biosciences, Bedford, MA). RPMI medium containing
50 % FBS was used as a chemoattractant in the lower
chamber. After 1-h incubation, GH (1 and 10 ng/ml)
was then added to upper and lower chambers. Three
days later, cells on the upper surface of the filters
were removed by wiping with a cotton swab. Cells
that penetrated the pores to the lower surface of fil-
ters were stained with 0.05 % crystal violet solution
(in 20 % methanol). The cells in three random fields
per well were photographed and counted using an
inverted microscope.
Pulmonary metastasis
B16F10 cells (6 × 104) were injected into the femoral
vein of mice. Three weeks later, the mice were eutha-
nized and lung nodules were photographed and counted
using a dissecting microscope.
Administration of growth hormone and prolactin in mice
Mice were intravenously injected with B16F10 cells
(6 × 104). GH or prolactin (5 mg/kg each; R&D system,
Minneapolis, MN, USA) were then subcutaneously
injected into mice, twice per week for three weeks.
Murine melanoma cells with knockdown of GHR
B16F10 murine melanoma cells were maintained in
RPMI medium supplemented with 10 % heat-inactivated
FBS, 100 U/ml penicillin, and 0.1 mg/ml streptomycin
(Invitrogen, Carlsbad, CA). Knockdown of GHR in the
cells was achieved by transfecting the cells with a plas-
mid vector carrying shRNA, which targets GHR tran-
scripts (target Sequence: CCCGACTTCTACAATGATG
AT), whereas cells transfected with an empty plasmid
vector, i.e. pLKO.1, were used as the control. Melanoma
cells were transfected with plasmid vectors, using the
Oligofectamine reagent (Invitrogen, Carlsbad, CA)
dissolved in Opti-MEM medium (Life Technologies, Van
Allen Way, Carlsbad, CA, USA). Six hours after trans-
fection, the medium was replaced with RPMI medium,
and puromycin (1 ng/ml) was added to the cultured
medium to kill cells lacking chromosomal integration of
the gene. A stably transfected pool was established
following selection with puromycin, and knockdown of
GHR was confirmed using Western blot analysis.
Statistical analysis
Statistical analysis was performed using the Student’s
t-test. Statistical comparisons of more than two
groups were performed using one-way analysis of
variance (ANOVA) followed with Bonferroni’s post
hoc test. All data were presented as means ± SEM.
Differences were considered statistically significant at
P < 0.05.
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Results
Increase in growth hormone levels in lung tissue of DJ-1
knockout mice
We examined mRNA expression of GH in the lungs of
DJ-1 KO mice. The results of semi-quantitative PCR
(upper panels) and real-time quantitative PCR (lower
panels) showed that GH mRNA (Fig. 1a) increased in lung
tissue of DJ-1 KO mice and Western blot analysis further
confirmed the higher expression of GH protein in the lung
tissue of DJ-1 KO mice (Fig. 1b). On the other hand, it has
been reported that GH can promote cell survival and
proliferation through IGF-1 signaling [14]. We then exam-
ined the expression level of IGF-1 in DJ-1 KO mice. The
result showed that the mRNA levels of IGF-1 in lungs of
mice were not affected in DJ-1 KO mice (Fig. 1c).
Since GH levels were increased in the lung tissue of
DJ-1 KO mice, we also measured serum levels of GH.
As shown in Fig. 1d, no significant difference was ob-
served in the serum levels of GH between DJ-1 KO and
WT mice. These results suggest that GH was elevated
locally in the lung tissue of DJ-1 KO mice, but not sys-
temically in the circulation.
Fig. 1 Increase of growth hormone expression in the lungs of DJ-1 KO mice. Lung tissues were isolated from WT and DJ-1 KO mice and used for
semi-quantitative PCR (a, upper panel); real-time quantitative PCR (a, lower panel); and Western blotting (b). Note that there was an increase in GH
mRNA and protein expression levels in pulmonary tissue of DJ-1 KO mice. c Insulin-like growth factor 1 (IGF-1) mRNA expression in pulmonary
tissue and (d) serum levels of GH were not significantly different between WT and DJ-1 KO mice. Data are presented as mean ± SEM (n = 5 for
each group); *, P < 0.05 compared to WT. WT: wild type; KO: knockout; GH: growth hormone
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Growth hormone increases cell survival, proliferation,
colony formation, and invasive capacity of melanoma
cells
It has been reported that GH has an effect on human can-
cer cells, such as mammary carcinoma [18]. Moreover,
GHRs have been demonstrated in human and murine
melanoma cells [20, 23]. We therefore examined the
effects of GH on cultured melanoma cells. The MTTassay
was used to examine the viability of B16F10 cells, follow-
ing treatment with recombinant GH protein (at 0.5, 5, and
15 ng/ml) for 24 h. The results showed that GH could
enhance the viability of B16F10 cells in a concentration-
dependent manner (Fig. 2a). Furthermore, BrdU uptake
was used to examine the proliferation of B16F10 cells, fol-
lowing treatment with recombinant GH protein (0.5, 5,
and 15 ng/ml) for 24 h. The results showed that GH could
also increase the proliferation of B16F10 cells in a
concentration-dependent manner (Fig. 2b).
We further examined the effects of GH on colony
formation, which was an in vitro metastasis model.
B16F10 cells were seeded in agarose gel and treated with
recombinant GH protein for 12 d. The results showed
that GH increased colony formation of B16F10 cells
(Fig. 3a) up to 1.98-fold at 1 ng/ml GH. In cell invasion
analysis, B16F10 cells were seeded on transwell culture
inserts with filters, which were pre-coated with Matrigel,
and treated with recombinant GH protein. The results
showed that treatment with GH for 3 d increased
invasion of B16F10 cells in a concentration-dependent
manner (Fig. 3b). The invasive capacity of melanoma
cells increased up to 2.25-fold at 10 ng/ml GH. These
results suggest that GH administration can enhance the
malignant potential of B16F10 melanoma cells.
Growth hormone increases the expression of matrix
metalloproteinases in melanoma cells
Some members of the MMP family play a role in tumor
cell invasion because their effects can lead to degradation
of the extracellular matrix. We therefore examined
whether MMP levels were enhanced by treatment with
GH. B16F10 melanoma cells were treated with various
doses (0.1, 1, and 10 ng/ml) of GH for 3 h (Fig. 4a), and
then at various time intervals (0, 1, 3 and 6 h) at GH
10 ng/ml (Fig. 4b; F = 22.362, P < 0.05). Cells were col-
lected and mRNA expression of MMP-2 was examined
using RT-PCR. The results showed that GH increased the
expression levels of MMP-2 mRNA in a concentration-
and time-dependent manner. We then treated B16F10
cells with GH (0.1, 1, and 10 ng/ml) for 6 h and proteins
were prepared for Western blotting. It was found that GH
also increased expression of MMP-2 protein (Fig. 4c; F =
27.471, P < 0.05) in a concentration-dependent manner.
According to previous reports, GH binds to GHRs and ac-
tivates nonreceptor tyrosine kinase, Janus kinase 2 (JAK2),
resulting in cellular effects [24]. We then used the JAK2
inhibitor, AG490 (Santa Cruz, CA, USA) to examine
whether it can antagonize the effect of GH. The results
showed that the GH-induced MMP-2 expression was
down-regulated by the treatment of JAK2 inhibitor
(Fig. 4d). In addition, we found that GH also enhanced the
protein expression of MMP-9 (Fig. 5a) and MMP-13
(Fig. 5b) in a concentration-dependent manner. These
results suggest that GH may enhance the invasive capacity
of B16F10 cells, by upregulating the expression of matrix
metalloproteinases.
Growth hormone increases lung nodule formation in
C57/B6 mice
Since GH can enhance the viability, proliferation, colony
formation, and invasive capacity of melanoma cells in
vitro, B16F10 cells (6 × 104) were injected into the
Fig. 2 Growth hormone enhances survival and proliferation of B16F10
melanoma cells. a Cell viability measured using the MTT assay. Note that
treatment of GH (0.5, 5, 15 ng/ml) increased cell viability of B16F10 cells
in a concentration-dependent manner. b Cell proliferation evaluated
using BrdU uptake analysis. Note that treatment of GH (0.5, 5, 15 ng/ml)
enhanced cell proliferation in a concentration-dependent manner. Data
are presented as mean ± SEM (n= 4 for each group); *, P< 0.05
compared to the control; BrdU, bromodeoxyuridine
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femoral vein of C57/B6 mice, which were then sub-
cutaneously injected with GH (5 mg/kg, twice/week).
Mice were sacrificed and lung tissues were isolated
three weeks later. We found that treatment with GH
increased the number of lung nodules by 1.69-fold
(Fig. 6a). Since prolactin is also secreted by the anter-
ior pituitary hormone and serves autocrine functions
[25] and prolactin receptor is expressed in melanoma
cells [19], we also examined the effect of prolactin on
melanoma growth in vivo. The results showed that
subcutaneous injection of prolactin (5 mg/kg, twice/
week) had no significant effect on lung nodule forma-
tion following intravenous injection of melanoma cells
in WT mice (Fig. 6b). These results suggest that GH
but not prolactin can enhance lung nodule formation
of intravenous melanoma cells.
Fig. 3 Growth hormone enhances colony formation and invasive capacity of B16F10 melanoma cells. a Colony formation of B16F10 cells in soft agar
with and without GH. Note that GH increased B16F10 cell colony formation in a concentration-dependent manner and colonies were photographed
and counted. b B16F10 cells were seeded into a transwell with 8-μm pore polycarbonate filters and matrix gel. Cells penetrated the pores to the lower
surface of filters and were stained with crystal violet and counted. The results showed that GH increased the invasive capacity of B16F10 cells in a
concentration-dependent manner. Data are presented as mean ± SEM (n = 4 for each group); *, P < 0.05 compared to the control. Scale bar = 0.2 mm
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Increased lung nodule formation in DJ-1 KO mice is
inhibited by knockdown of GHR in melanoma cells
Since GHR is expressed in melanoma cells [19] and GH
can enhance the malignant effects of B16F10 melanoma
cells in vitro and lung metastasis in vivo, we then used
GHR-knockdown B16F10 cells to examine the effects of
lung GH in DJ-1 KO mice. As demonstrated by Western
blot analysis, expression of the GHR protein was signifi-
cantly reduced in the cell pool that was stably transfected
with shRNA-plasmids (GHR-shRNA) in comparison to
the pool of empty plasmids (pLKO.1). This finding sug-
gests that stable knockdown of GHR was successfully
established in B16F10 melanoma cells (Fig. 7a). Following
intravenous injection of GHR-knockdown B16F10 cells to
both WT and DJ-1 KO mice, the increased lung nodule
formation in DJ-1 KO mice was inhibited (Fig. 7b). These
results suggest that up-regulation of GH in DJ-1-deficient
lungs plays a role in promoting the formation of lung
nodules.
Discussion
In the present study, we demonstrated that mRNA and
protein levels of GH were increased in the lungs of DJ-1
KO mice (Fig. 1). Furthermore, GH can increase the
Fig. 4 Growth hormone increases the expression of MMP-2 in B16F10 cells through JAK signaling. a Expression of MMP2 mRNA was increased
in B16F10 cells following 3 h of treatment with GH in a concentration-dependent manner. b MMP-2 expression was increased by 10 ng/ml in a time-
dependent manner. c B16F10 cells treated with GH (0.1, 1, 10 ng/ml) for 6 h increased expression of MMP-2 protein in a concentration-dependent manner.
d GH-induced increase of MMP-2 was inhibited by JAK inhibitor (AG490). Data are presented as mean ± SEM (n= 3 for each group); *, P< 0.05 compared
to the control (Con); #, P< 0.05 compared to GH treatment alone; JAK, Janus kinase
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viability, proliferation, and colony formation of melan-
oma cells (Figs. 2 and 3). We also found that GH could
up-regulate the expression of matrix metalloproteinases,
which promote the invasive capacity of melanoma cells
(Figs. 3, 4 and 5). Furthermore, we found that treatment
with GH increases lung nodule formation, following
intravenous injection of melanoma cells in wild-type
mice (Fig. 6) and increased lung nodule formation in DJ-
1 KO mice can be inhibited by intravenous injection of
GHR-deficient melanoma cells (Fig. 7).
B16F10 melanoma cells were used because they are
poorly immunogenic and do not express GH [19, 26], so
that we can rule out any GH-derived effects caused by
cancer cells. Moreover, several studies have shown that
melanoma cell lines express high levels of growth hor-
mone receptor and respond to GH treatment. On the
other hand, DJ-1 KO mice were used because melanoma
or breast cancer is increased in patients with Parkinson's
disease according to accumulating epidemiological data
[27]. We here thus further explored the connection
between cancer and the neurodegenerative disease. Not-
ably, Tillman et al. reported that DJ-1 could directly
regulate the activity of the androgen receptor to pro-
mote the progression of prostate cancer [28]. Flutamide,
an androgen receptor antagonist, can increase the
expression of DJ-1 in prostate cancer cell lines by in-
creasing DJ-1 protein stabilization [29]. Another study
also indicated that blocking an androgen receptor with
flutamide enhances secretion of GH [30]. These results
demonstrate that DJ-1 can mediate the progression of
hormone-regulated cancer and suggest that there may
be a connection between DJ-1 and GH. In the present
study, we found that with DJ-1 deficiency, there was a
concurrent increase in GH in lung tissue. The relation-
ship among GH, DJ-1, and androgen receptor inhibition
requires further investigation.
According to previous studies, GH has a half-life in
the serum of only 4–20 mins in animals and human
and basal serum level in mice is 8.7 ± 6.5 (<20 ng/ml)
[31, 32]. As shown in Fig. 1d, we found that the mean
serum level of GH (0.77–2.68 ng/ml) was in the range
as reported previously, so that the serum level of GH
was normal in DJ-1 knockout mice. In human, the basal
level of hGH was 0.63 ± 0.91 [33]. However, unlike in
murine lung, GH does not play a direct physiological
role in growth and maturation of human lung [34].
Therefore, there may be some species differences in
the regulation of lung development by GH. Here we
found that expression level of GH was increased in
lungs of DJ-1 KO mice as compared with those of
WT mice (Fig. 1). Moreover, we also found that levels
of GH were up-regulated in spleen and liver of DJ-1
KO mice (Additional file 1: Figure S1). According to
former reporters, spleen can produce GH to enhance
Fig. 5 Growth hormone enhances the expression of MMP-9 and
MMP-13 in B16F10 cells. The protein levels of MMP-9 (a) and MMP-13
(b) in B16F10 cells were up-regulated in a concentration-dependent
manner following GH treatment (0.1, 1, 10 ng/ml) for 6 h. Data are
presented as mean ± SEM (n = 3 for each group); *, P < 0.05 compared
to the control (Con)
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the maturation of myeloid progenitor cells and liver
is a major target organ of GH [35, 36]. However, fur-
ther experiments are needed to examine their roles
and effects in DJ-1 KO mice. As shown in Figs. 2, 3,
4 and 5, we found that GH not only promoted cell
proliferation (Fig. 2) but also enhanced cell invasion
(Fig. 3). Matrix metalloproteinases upregulation may
be involved in the increase of invasion ability (Figs. 4
and 5). Therefore, the increase of lung nodules is not
simply a product of increased proliferation induced by
GH. GH can enhance other malignant effects of
B16F10 cells when tumor cells initiate and grow.
As reported previously, the most common experimental
metastasis model is vein injection, which primarily results
in lung metastases [37]. Furthermore, it was found that
B16-F10, chosen in our study, formed only lung tumor
nodules after intravenous injection, whereas B16-F1
yielded some extrapulmonary tumor nodules [38]. There-
fore, it demonstrates that lung is the main metastatic
organ for B16F10 cells. Despite the increased levels of GH
in spleen and liver of DJ-1 KO mice, we focus on the lung
nodules formation following intravenous injection of
B16F10 cells (Figs. 6 and 7). Notably, a stably transfected
pool in cell culture was established following puromycin
selection. According to previous studies, a puromycin-
resistant gene is commonly used as a selection marker in
mammalian cells, since puromycin is toxic to the growth
of mammalian cells [39]. Therefore, we infer that puro-
mycin treatment might slightly affect malignant effects of
B16F10 melanoma cells, so that the lung nodules were
reduced in results of Fig. 7 as compared with the injection
of non-treated B16F10 cells. Moreover, the use of
pLKO.1-melanoma cells as control cells can rule out any
effects caused by puromycin selection procedures. How-
ever, the possible cause of less nodule formation needs
further examination. In addition, Sustarsic et al. (2013)
has reported that melanoma express the highest level of
GHR among several human cancer cells of NCI60 panel
(US National Cancer Institute’s Development Therapeutics
Program). Other studies have also shown that targeting
GHR can control cancer metastasis, such as pancreatic
cancer [40]. In this study, we found that GHR down-
regulation reduced lung metastasis of melanoma cells
(Fig. 7). However, it needs further examination to verify
whether up-regulated expression of GHR in melanoma can
increase the incidence of lung metastasis. Furthermore, we
Fig. 6 Growth hormone enhances lung nodule formation in C57/B6 mice. B16F10 cells (6 × 104 cells) were injected into the femoral vein of C57/B6
mice. The mice were subcutaneously injected with GH (a) or prolactin (b) (5 mg/kg, twice/week, respectively). The lung nodules were photographed
and counted three weeks later. Results showed an increase in the number of lung nodules in C57/B6 mice following GH administration and there was
on difference after prolactin administration. Data are presented as mean ± SEM (n = 11–12 for each group in a; n = 5 for each group in b); *, P < 0.05
compared to the control. Scale bar = 3 mm
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found that the source of increased GH was autocrine from
lung tissue of DJ-1 KO mice and the cancer cells were
affected by the paracrine GH. According to previous
reports, GH can increase STAT5 phosphorylation in meta-
static melanoma cells and STAT5 activation is associated
with enhanced invasion and metastasis of melanoma [19].
Therefore, we infer that the GH-overexpressing cancer cells
should enhance tumor metastasis in control mice as similar
as the injection of normal cancer cells in DJ-1 KO mice.
In fact, we found that GH treatment did not affect
body weight of mice (data not shown). According to
the former studies, GH has been shown to enhance
immune function by starting both neutrophils and
macrophages for production of cytokines and super-
oxide anions [41, 42]. GH also acts as a cytokine that
induces survival and proliferation of lymphoid cells through
the PI-3 kinase/Akt pathway and NF-κB [43]. Moreover,
exogenous GH increases levels of superoxide in alveolar
macrophages [44]; increases production of NF-κB [45] and
lung phosphorylase A activity [46]; suppresses glutathione
peroxidase (GPX) and manganese superoxide dismutase
(MnSOD) protein levels and activity [47]; and stimu-
lates tyrosine phosphorylation of specific proteins in
lung epithelial cells [16]. These effects of GH can all
make cancer cells more invasive in the microenviron-
ment of the lung, by reducing antioxidative defense
and enhancing inflammatory signaling. However, it was
found that GH can not increase the influx of neutro-
phils into lungs by measuring MPO activity and not
enhance lung microvascular permeability by using
Evan’s blue dye [45]. Taken together, we infer that
there is an altered immune-microenvironment in lungs
by GH treatment, which enhances lung metastasis of
B16F10 cells through up-regulating levels of super-
oxide in alveolar macrophages and inhibiting expres-
sion of superoxide dismutase enzyme. In addition, our
results showed that there was no significant difference
in serum levels of GH between WT and DJ-1 KO mice,
regardless of whether they had been injected with
B16F10 cells (Additional file 1: Figure S2). Therefore,
Fig. 7 Elevated lung nodule formation in DJ-1 KO mice is suppressed following injection of GHR-knockdown melanoma cells. a Western blots
showed the knockdown of GHR in B16F10 melanoma cells. Upper panel: representative blots of GHR and actin in cells stably transfected with
empty plasmids (pLKO.1) or plasmids encoding GHR shRNA. Lower panel: bar chart showing statistical results of the Western blot. b B16F10 cells
(6 × 104) transfected with pLKO.1 plasmids (pLKO.1-melanoma) or GHR shRNA plasmids (GHR-knockdown-melanoma) were intravenously injected
into mice. Three weeks later, mice were sacrificed. Gross images (upper) showed the melanoma nodules (arrows in the panel) and bar chart (lower)
showed the summarized results of lung nodule numbers in WT and DJ-1 KO mice. Note that melanoma nodule formation was enhanced in DJ-1
KO mice following injection of pLKO.1-melanoma cells, but was suppressed following injection of GHR-knockdown melanoma cells. Data are
presented as mean ± SEM (n = 5 for each group); *, P < 0.05 compared to the control, WT mice with pLKO.1-melanoma; #, P < 0.05 compared to
DJ-1 KO mice with pLKO.1-melanoma. Scale bars = 0.5 mm
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we can infer that GH might play a local inflammatory
role that promotes the growth of tumor cells, particu-
larly in the early stages of lung metastasis.
A link between inflammation and cancer has been
observed in tumor biopsy specimens [48]. The mecha-
nisms underlying the connection between inflammation
and tumorigenesis have been studied within the last
decade. The balance between immunosurveillance and
tumor-promoting inflammation is quite important in
the tumor microenvironment [49]. Inflammatory cells
producing reactive oxygen species (ROS), cytokines,
chemokines, MMPs, and prostaglandin E2 (PGE2) amp-
lify the signaling cascade of inflammation [50]. Further-
more, some reports suggest that mitochondrial ROS is
an important intermediate in inflammation-associated
cancer [51]. DJ-1 mutant-associated Parkinson’s disease
is in fact related to mitochondrial dysfunction and up-
regulation of ROS [52]. Using gelatin zymography, we also
found that DJ-1 deficiency enhanced the activity of MMP-
2, MMP-9, and MMP-13 in lung tissue (Additional file 1:
Figure S3). Therefore, inflammatory reactions and factors
promoting the development of cancer cells may exist in
DJ-1 KO mice, which might explain why increased metas-
tasis to the lungs can be readily observed in DJ-1 KO
mice. Nevertheless, further research is necessary to deter-
mine whether up-regulated activity of matrix metallopro-
teinases is correlated with GH levels in the lungs of DJ-1
KO mice.
Conclusion
In summary, both mRNA and protein levels of GH are
increased in the lungs of DJ-1 KO mice. Moreover, GH
can enhance the malignant effects of B16F10 cells and
play a regulatory role in nodule formation of melanoma
in lung metastasis. Furthermore increased lung nodule
formation in DJ-1 KO mice is inhibited by intravenous
injection of GHR-deficient melanoma cells.
Additional file
Additional file 1: Figure S1. Up-regulated expression of growth
hormone in spleen and liver of DJ-1 KO mice. Figure S2. Serum levels of
growth hormone do not be affected in mice injected with B16F10 cells.
Figure S3. Enhanced enzyme activity of MMP proteins in lungs of DJ-1
KO mice. (DOC 691 kb)
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